Rhythm Pharmaceuticals Wins Japan Approval for IMCIVREE
BOSTON, August 24, 2026 Rhythm Pharmaceuticals, Inc. announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted...
MC4R Agonist
Advertisement
Tasman Therapeutics Advances R-107 with Osmind Partnership
San Francisco, California, August 12, 2026 Tasman Therapeutics announced a multi-year strategic partnership with Osmind to support the development...
Rhythm Pharmaceuticals Expands IMCIVREE Authorization in UK
Boston, Massachusetts, August 11, 2026 Rhythm Pharmaceuticals announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA)...
Rhythm Pharmaceuticals Advances RM-718 with Promising Phase 2 Obesity Trial Results
BOSTON, August 4, 2026 Rhythm Pharmaceuticals announced encouraging preliminary Phase 2 clinical trial results for RM-718, its investigational once-weekly...
Rhythm Publishes Phase 3 IMCIVREE Data in NEJM
BOSTON, Mass., July 8, 2026 Rhythm Pharmaceuticals announced that the New England Journal of Medicine (NEJM) has published the...
Advertisements
Rhythm Pharmaceuticals Secures EU Approval for IMCIVREE
BOSTON, MA, May 1, 2026 Rhythm Pharmaceuticals, Inc. announced that the European Commission has granted marketing authorization for IMCIVREE®...
Advertisement
